Joshua Lewis

University of Maryland, Baltimore

1 active project

Assessment of Feasibility to Study Antiplatelet Pharmacogenomics

The purpose of this research is to establish whether it is feasible to study the pharmacogenomic determinants of antiplatelet therapy response in the AllofUs Program. We would like to estimate the number of participants who have been prescribed various antiplatelet…

Scientific Questions Being Studied

The purpose of this research is to establish whether it is feasible to study the pharmacogenomic determinants of antiplatelet therapy response in the AllofUs Program. We would like to estimate the number of participants who have been prescribed various antiplatelet agents (e.g. clopidogrel, ticagrelor, etc.) as well as the subset of individuals who have experienced a major adverse cardiovascular event during therapy. If feasible, ultimately we would like to identify genetic variants that impact the rates of on-treatment cardiovascular events.

Project Purpose(s)

  • Ancestry

Scientific Approaches

We would like to define cohorts based on antiplatelet medication usage and relevant cardiovascular events using the Cohort Builder and Dataset Builder. Specifically, we will query the number of patients who have been prescribed antiplatelet agents such as clopidogrel, ticagrelor, aspirin, etc. Furthermore, we would like to ascertain the number of patients who have experienced a major adverse cardiovascular event while on therapy. Assuming the sample size seems adequate, power analyses may be performed to determine if genetic analyses are warranted. If it is deemed feasible, a robust analytical strategy will be developed to test for association between genetic markers and related clinical phenotypes in patients who have been prescribed antiplatelet therapy.

Anticipated Findings

We anticipate the AllofUs dataset will contain an adequate number of data points to assess the association between genetic variants and cardiovascular endpoints in those prescribed antiplatelet therapy...at least for those medications that are more commonly prescribed. Assuming the dataset is sufficiently powered, we anticipate that we would be to identify genetic variation that influences antiplatelet therapy response.

Cardiovascular disease remains one of the leading causes of death in the United States. Antiplatelet therapy is routinely used to reduce the rates of recurrent cardiovascular events in those who have suffered an initial event. Understanding the factors that influence response to treatment not only allows us to better understand the mechanistic underpinnings of variable antiplatelet response but may also lead to more personalized strategies to reduce adverse clinical outcomes in those who are prescribed these medications.

Demographic Categories of Interest

This study will not center on underrepresented populations.

Data Set Used

Controlled Tier

Research Team

Owner:

1 - 1 of 1
<
>
Request a Review of this Research Project

You can request that the All of Us Resource Access Board (RAB) review a research purpose description if you have concerns that this research project may stigmatize All of Us participants or violate the Data User Code of Conduct in some other way. To request a review, you must fill in a form, which you can access by selecting ‘request a review’ below.